Patents Assigned to SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD.
  • OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR
    Publication number: 20240109895
    Abstract: An oxaspiro substituted pyrrolopyrazole derivative, an intermediate thereof, and a preparation method therefor.
    Type: Application
    Filed: December 29, 2021
    Publication date: April 4, 2024
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhenya ZENG, Chao KAN, Qingfu GAO, Yixiao FENG, Bo WU, Xingsong ZHANG, Youhong MA, Kejun SUN
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE DERIVATIVES, COMPOSITIONS AND PHARMACEUTICAL USES THEREOF
    Publication number: 20240109898
    Abstract: A substituted pyrazolo[1,5-alpyrimidin-7-amine derivative, the structure of which is represented by formula (1), or pharmaceutically acceptable salts, solvates, stereoisomers, prodrugs, drug compositions thereof. The derivative has significant CDK9-selective inhibitory activity.
    Type: Application
    Filed: January 21, 2022
    Publication date: April 4, 2024
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhiming ZHAO, Shenghua WU, Mojia HUA, Yang LIU, Shenglei HAO, Lulu WANG
  • HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF
    Publication number: 20240025924
    Abstract: Provided is a heterocycle substituted ketone derivative, the structure of which is as shown in formula (I). Further provided are a pharmaceutically acceptable salt of the derivative, a stereoisomer thereof, a pharmaceutical composition and the medicinal use thereof.
    Type: Application
    Filed: March 23, 2022
    Publication date: January 25, 2024
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Weixing ZHU, Qiang LIU, Xuhui HAO, Yonggang CHEN, Shaobo LI, Shanghua HE, Xiaotian HUANG, Zhiming ZHAO
  • SOLID PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230149402
    Abstract: The present invention relates to a solid pharmaceutical preparation and a preparation method therefor. Specifically, disclosed are a solid pharmaceutical preparation that comprises an orexin receptor antagonist compound and a preparation method therefor, the solid pharmaceutical preparation comprising an active ingredient of a compound represented by formula I, a filler, a binder, a disintegrant, and a lubricant. The solid pharmaceutical preparation has good dissolution, stability and in vivo bioavailability.
    Type: Application
    Filed: April 14, 2021
    Publication date: May 18, 2023
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Taotao JIANG, Jibiao WANG, Han YANG, Li LI, Zhaoling DAN, Keyi ZHU, Zhenya ZENG, Bo SU, Xi CHEN
  • SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF
    Publication number: 20230145793
    Abstract: Provided is a substituted pyrimidine or pyridine amine derivative represented by formula (I), and a pharmaceutically acceptable salt, solvate, stereoisomer, prodrug, and pharmaceutical composition thereof, as well as medical application thereof. The derivative has significant adenosine A2A receptor and/or adenosine A2B receptor antagonistic activities.
    Type: Application
    Filed: March 16, 2021
    Publication date: May 11, 2023
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Lifeng LIU, Zhiming ZHAO, Feng XU, Hailong WANG, Baoxin XI, Zhongan TONG, Huiping GUAN
  • Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof
    Patent number: 11174254
    Abstract: The present invention relates to a 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative substituted by N-(3-aminophenyl)acrylamide and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and a preparation method and application of the same. The definition of each substituent in the formula is described in detail in the specification and claims.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 16, 2021
    Assignees: YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD., SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Shuchun Guo, Fusheng Zhou, Xiang Chen, Jinzhu Zhao, Dong Huang, Jing Xie, Changjiang Qiao, Wan He, Kai Zhang, Xi Chen, Jiong Lan
  • 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
    Patent number: 11155546
    Abstract: The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: October 26, 2021
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Shuchun Guo, Fusheng Zhou, Xiang Chen, Jinzhu Zhao, Dong Huang, Jing Xie, Changjiang Qiao, Wan He, Kai Zhang, Xi Chen, Jiong Lan
  • Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
    Patent number: 10912775
    Abstract: Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: February 9, 2021
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Songliang Wu, Zhi Luo, Yuan Chen, Yuhe Wang, Dakun Qin, Xiaolin Li, Zheng Wang, Weidong Li, Haiying He
  • Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
    Patent number: 10898486
    Abstract: Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: January 26, 2021
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Songliang Wu, Zhi Luo, Yuan Chen, Yuhe Wang, Dakun Qin, Xiaolin Li, Zheng Wang, Weidong Li, Haiying He
  • Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
    Patent number: 10874674
    Abstract: Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: December 29, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Songliang Wu, Zhi Luo, Yuan Chen, Yuhe Wang, Dakun Qin, Xiaolin Li, Zheng Wang, Weidong Li, Haiying He
  • N-sulfonyl benzamides as voltage-gated sodium channel inhibitors
    Patent number: 10815197
    Abstract: The present invention discloses an N-sulfonyl benzamide derivative with a heterocyclic substituent, and a preparation method therefor and a pharmaceutical application thereof. More specifically, the invention discloses a compound represented by formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvent compound, or prodrug thereof, and a preparation method therefor and an application thereof. Refer to the specification for definitions of each group in the formula.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 27, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Fusheng Zhou, Jinzhu Zhao, Dong Huang, Jing Xie, Yi Hu, Qiang Lv
  • Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof
    Patent number: 10793549
    Abstract: The present invention relates to a sulfuryl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: October 6, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yunzhou Jin, Xiang Chen, Pengfei Cheng, Ping Bu, Leitao Zhang, Chong Wen, Yingtao Liu, Fusheng Zhou, Ming Weng, Jiong Lan
  • CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20200253972
    Abstract: Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Applicants: Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd.
    Inventors: Songliang WU, Zhi LUO, Yuan CHEN, Yuhe WANG, Dakun QIN, Xiaolin LI, Zheng WANG, Weidong LI, Haiying HE
  • Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
    Patent number: 10668066
    Abstract: Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of the preparing the orexin receptor antagonist compound 5-3 and its crystalline forms, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: June 2, 2020
    Assignees: Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd.
    Inventors: Songliang Wu, Zhi Luo, Yuan Chen, Yuhe Wang, Dakun Qin, Xiaolin Li, Zheng Wang, Weidong Li, Haiying He
  • Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof
    Patent number: 10577346
    Abstract: It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: March 3, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Fusheng Zhou, Shuchun Guo, Jinzhu Zhao, Hui Xu, Xia Shi, Yi Hu, Yufeng Li, Jiong Lan
  • EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
    Patent number: 10561646
    Abstract: Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: February 18, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Taotao Jiang, Daofei Li, Xing Liu
  • PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
    Patent number: 10544137
    Abstract: The present invention relates to a PI3K inhibitor, and a pharmaceutically acceptable salt, polycrystalline form, and application thereof. The invention specifically provides a polycrystalline form of 4-chloro-5-(6-(1-(methylsulfonyl)cyclopropyl)-2-morpholinopyrimidin-4-yl)pyridin-2-amine, a pharmaceutically acceptable salt thereof, or a polycrystalline form of the salt. The invention further discloses a pharmaceutical composition comprising the inhibitor and an application of the pharmaceutical composition.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: January 28, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Taotao Jiang, Qiang Xu, Zhaoling Dan
  • 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
    Patent number: 10435400
    Abstract: The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 8, 2019
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Yunzhou Jin, Fusheng Zhou, Jing Xie, Sida Shen, Yi Hu, Wei Liu, Qiang Lv
  • PI3K INHIBITOR, AND PHARMACEUTICALLY ACCEPTABLE SALT, POLYCRYSTALLINE FORM, AND APPLICATION THEREOF
    Publication number: 20190152964
    Abstract: The present invention relates to a PI3K inhibitor, and a pharmaceutically acceptable salt, polycrystalline form, and application thereof. The invention specifically provides a polycrystalline form of 4-chloro-5-(6-(1-(methylsulfonyl)cyclopropyl)-2-morpholinopyrimidin-4-yl)pyridin-2-amine, a pharmaceutically acceptable salt thereof, or a polycrystalline form of the salt. The invention further discloses a pharmaceutical composition comprising the inhibitor and an application of the pharmaceutical composition.
    Type: Application
    Filed: May 31, 2017
    Publication date: May 23, 2019
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Taotao JIANG, Qiang XU, Zhaoling DAN
  • 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
    Patent number: 10227324
    Abstract: Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (1) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: March 12, 2019
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Sida Shen, Xiaojing Ni, Zhiyuan Zhang, Zheng Yang, Xiangyu He, Weiwei Wang, Fusheng Zhou